ReviewFrontiers in cell and developmental biology2025
Gut microbiota therapy in gastrointestinal diseases.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Recent advances and clinical relevance of microbiome dynamics in health and disease.Gut microbes · 2026Review
- Indole-3-Propionic Acid Alleviates Metabolic Dysfunction-Associated Fatty Liver Disease via AHR/AMPK Signaling Activation.Food science & nutrition · 2026Article
- Personalized Medicine in Gastrointestinal Diseases: From Molecular Insights to Precision Clinical Care.Journal of personalized medicine · 2026Article
- Therapeutic Potential of Polysaccharide-Modulated Gut Microbiota-Immune Axis in Gastrointestinal Cancers: Modern Insights From Traditional Pharmacy.Molecular nutrition & food research · 2026Review
- Bortezomib-induced gastrointestinal dysfunction, peripheral neuropathy and neuroimmune signalling are influenced by the gut microbiota in mice.Journal of neuroinflammation · 2026Article
- Functional Reconstruction of the Gut Microecosystem in Gastrointestinal Motility Disorders: Roles of Probiotics, Prebiotics, Synbiotics and Postbiotics.Probiotics and antimicrobial proteins · 2026Review
- Dietary Therapies for Gastrointestinal Disorders.Nutrients · 2026Review
- The Barrier-Microbiota-Inflammation Axis in Colorectal Cancer: Mechanisms and Emerging Diagnostic & Therapeutic Strategies.Cancers · 2026Review
- The impact of implicit health symbols on probiotic products on purchase intention among gastrointestinal disease patients: evidence from multiple experiments.Frontiers in nutrition · 2026Article
- The gut-brain axis in Alzheimer's disease: early detection, microbial metabolites, mechanisms, and therapeutic opportunities.Frontiers in molecular biosciences · 2026Review
- Evaluating the anti-gut dysbiotic potential of bioactive primary metabolites derivatives fromFrontiers in nutrition · 2026Article
- Antimicrobial resistance in Gram-negative bacteria from retail meat: Prevalence and public health implications.PloS one · 2026Article
- Article
- Molecular Mechanisms of Probiotic Action Against Gastrointestinal Cancers.International journal of molecular sciences · 2025Review
- Regulatory and Influencing Factors of Digestive Function in Elderly People: Roles of the Gut Microbiota and Nutritional Interventions.Aging and disease · 2025Review
- Prevalence and antimicrobial drug resistance of gram-negative bacteria in dairy feed and water: a One Health concern.Frontiers in veterinary science · 2025Article
- The impact of trans fatty acids on ADHD in relation to the gut microbiome.Frontiers in nutrition · 2025Review
- Dissecting the intratumoral microbiome landscape in lung cancer.Frontiers in immunology · 2025Review
- Gut-brain axis and vascular dementia: a review on mechanisms and Chinese herbal medicine therapeutics.Frontiers in microbiology · 2025Review
- The microbiome and lung cancer: microbial effects on host immune responses and treatment outcomes.Frontiers in microbiomes · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human gut microbiota, consisting of trillions of microorganisms, plays a crucial role in gastrointestinal (GI) health and disease. Dysbiosis, an imbalance in microbial composition, has been linked to a range of GI disorders, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, and colorectal cancer. These conditions are influenced by the interactions between the gut microbiota, the host immune system, and the gut-brain axis. Recent research has highlighted the potential for microbiome-based therapeutic strategies, such as probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary modifications, to restore microbial balance and alleviate disease symptoms. This review examines the role of gut microbiota in the pathogenesis of common gastrointestinal diseases and explores emerging therapeutic approaches aimed at modulating the microbiome. We discuss the scientific foundations of these interventions, their clinical effectiveness, and the challenges in their implementation. The review underscores the therapeutic potential of microbiome-targeted treatments as a novel approach to managing GI disorders, offering personalized and alternative options to conventional therapies. As research in this field continues to evolve, microbiome-based interventions hold promise for improving the treatment and prevention of gastrointestinal diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.